NCT00224029View on ClinicalTrials.gov

A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition

PHASE4CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

December 31, 2005

Study Completion Date

May 31, 2008

Conditions
Detrusor Hyperreflexia
Interventions
DRUG

Oxybutynin transdermal system

3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day transdermal per titration

Trial Locations (6)

Unknown

Atlanta

The Bronx

Chapel Hill

Charlotte

Dallas

Houston

Sponsors
All Listed Sponsors
lead

Watson Pharmaceuticals

INDUSTRY

NCT00224029 - A Study Evaluating Oxybutynin in Patients With Neurogenic Overactive Bladder Associated With a Neurological Condition | Biotech Hunter | Biotech Hunter